Accelerating IMPT-314 in large B-cell lymphoma; remain on track to initiate pivotal trial in the 3rd line+ setting in 2025 and expect to initiate ...

On Astellas Pharma’s mission to develop new cell therapies in cancers and other diseases, not all candidates are destined to ...

A phase 3 trial reveals that combining brentuximab vedotin with lenalidomide and rituximab improves survival in relapsed ...

Research shows routine follow-up misses most relapses in lymphoma patients in remission, highlighting the need for improved ...

BOULDER, Colo., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Foresight Diagnostics (Foresight), a leader in ultra-sensitive minimal residual disease (MRD) detection technology, today provided its strategic ...

Panelists discuss the key challenges faced by patients with diffuse large B-cell lymphoma and follicular lymphoma at diagnosis, how these challenges evolve during treatment, and the emotional and ...

As we start the New Year, it’s time to schedule your annual wellness visit. This important appointment is to talk about any ...

In recent years, the FDA has amped up its supervision of accelerated approvals, including by requiring that confirmatory ...

The ASX dipped a tad on Friday, while uranium miners rose after Cameco halted production. Also… news just in – Trudeau looks set to quit.

ASX rides Wall Street’s bounce, energy stocks soar, Insignia jumps on takeover bid and Bellevue Gold takes a dive.

Knight Therapeutics Inc. (TSE:GUD – Get Free Report)’s stock price was up 0.6% during mid-day trading on Friday . The company traded as high as C$5.41 and last traded at C$5.37. Approximately 22,259 ...

Oreofe Odejide had always wanted to be a doctor after spending much time growing up accompanying her father on his rounds as an obstetrician–gynaecologist in Ile-Ife, Nigeria. And with her mum a ...